Anadys' hepatitis C drug shows promise in midstage trial

12/17/2009 | Reuters

An experimental hepatitis C drug from Anadys Pharmaceuticals helped reduce the virus to an undetectable level in 56% of midstage-trial patients, compared with 20% of the placebo group, after four weeks of treatment. ANA598 was combined with pegylated interferon and ribavirin, a standard therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC